Trial Profile
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms OASIS (CM); OASIS PEDIATRIC (CM)
- Sponsors Amgen
- 06 Sep 2023 Planned End Date changed from 4 Apr 2027 to 28 Jun 2027.
- 06 Sep 2023 Planned primary completion date changed from 5 Apr 2026 to 29 Jun 2026.
- 03 May 2023 Planned End Date changed from 28 Jun 2027 to 4 Apr 2027.